MetaSight Diagnostics
MetaSight pioneers the development of accurate, affordable, and accessible disease diagnostics and monitoring through advanced blood testing, designed for high-volume population-scale screening. They utilize a robust discovery platform integrating proprietary high throughput mass-spectrometry multi-OMICs technology, population-scale serum samples collection, and electronic health records to create the world's largest blood molecular database, driving innovation in disease diagnostics and monitoring.
Industries
Nr. of Employees
small (1-50)
Products
Blood-based assay for MASH-associated liver fibrosis (proteomics-based)
A serum proteomics-derived diagnostic and monitoring assay targeting three serum biomarkers to detect significant or advanced fibrosis in patients with metabolic dysfunction-associated steatohepatitis; intended for CLIA/LDT deployment and clinical-trial use.
Serum lipid biomarker discovery program for colorectal cancer
Discovery program identifying serum lipid biomarkers with strong association to colorectal cancer from untargeted LC-MS multi-omics screening.
Blood-based assay for MASH-associated liver fibrosis (proteomics-based)
A serum proteomics-derived diagnostic and monitoring assay targeting three serum biomarkers to detect significant or advanced fibrosis in patients with metabolic dysfunction-associated steatohepatitis; intended for CLIA/LDT deployment and clinical-trial use.
Serum lipid biomarker discovery program for colorectal cancer
Discovery program identifying serum lipid biomarkers with strong association to colorectal cancer from untargeted LC-MS multi-omics screening.
Services
Population-scale multi-omics discovery studies
Design and execution of large-scale untargeted LC-MS multi-omics screening studies with linked de-identified EHRs for biomarker discovery and signature derivation.
Population-scale multi-omics discovery studies
Design and execution of large-scale untargeted LC-MS multi-omics screening studies with linked de-identified EHRs for biomarker discovery and signature derivation.
Expertise Areas
- Mass-spectrometry based metabolomics
- Lipidomics and proteomics
- Population-scale biomarker discovery
- EHR-linked observational studies
Key Technologies
- Untargeted LC-MS metabolomics
- Targeted LC-MS assays
- High-throughput mass spectrometry
- Lipidomics